Search

Background: In the SPOTLIGHT trial (Spot Sign Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy), patients with a computed tomography (CT) angiography spot-sign positive acute intracerebral hemorrhage were randomized to rFVIIa (recombinant activated factor VIIa; 80 μg/kg) or placebo within 6 hours of onset, aiming to limit hematoma expansion. Administration of rFVIIa did not significantly reduce hematoma expansion. In this prespecified analysis, we aimed to investigate the impact of delays from baseline imaging to study drug administration on hematoma expansion. Methods: Hematoma volumes were measured on the baseline CT, early post-dose CT, and 24 hours CT scans. Total hematoma volume (intracerebral hemorrhage+intraventricular hemorrhage) change between the 3 scans was calculated as an estimate of how much hematoma expansion occurred before and after studying drug administration. Results: Of the 50 patients included in the trial, 44 had an early post-dose CT scan. Median time (interquartile range) from onset to baseline CT was 1.4 hours (1.2–2.6). Median time from baseline CT to study drug was 62.5 (55–80) minutes, and from study drug to early post-dose CT was 19 (14.5–30) minutes. Median (interquartile range) total hematoma volume increased from baseline CT to early post-dose CT by 10.0 mL (−0.7 to 18.5) in the rFVIIa arm and 5.4 mL (1.8–8.3) in the placebo arm ( P =0.96). Median volume change between the early post-dose CT and follow-up scan was 0.6 mL (−2.6 to 8.3) in the rFVIIa arm and 0.7 mL (−1.6 to 2.1) in the placebo arm ( P =0.98). Total hematoma volume decreased between the early post-dose CT and 24-hour scan in 44.2% of cases (rFVIIa 38.9% and placebo 48%). The adjusted hematoma growth in volume immediately post dose for FVIIa was 0.998 times that of placebo ([95% CI, 0.71–1.43]; P =0.99). The hourly growth in FFVIIa was 0.998 times that for placebo ([95% CI, 0.994–1.003]; P =0.50; Table 3). Conclusions: In the SPOTLIGHT trial, the adjusted hematoma volume growth was not associated with Factor VIIa treatment. Most hematoma expansion occurred between the baseline CT and the early post-dose CT, limiting any potential treatment effect of hemostatic therapy. Future hemostatic trials must treat intracerebral hemorrhage patients earlier from onset, with minimal delay between baseline CT and drug administration. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01359202.

Hypothesis: There is considerable evidence that women have poor outcome following acute stroke when compared to men. We report our experience from a large prospective stroke database from Qatar. Methods: The Qatar stroke database is a prospective study, which began enrolling patients in 2014. We collected data on the demographics, clinical presentation, investigations, treatments, hospital complications and outcome (measured as 90-days modified Rankin Score [mRS]) on all patients admitted with acute stroke to the Hamad General Hospital where ~95% of stroke patients in Qatar are admitted. Multivariate analysis of risk factors, stroke type and severity, and in-hospital complications were compared to determine 90-days and one-year outcome in men and women. Results: There were 7300 stroke patients (women:1406 [19.3%], men:5894 [80.7%] admitted between 2014-2021. Multivariate analysis revealed significantly higher rates of obesity (OR 2.51), increasing age (age>65 years [OR 3.79]) and atrial fibrillation (OR 1.26) in women, p Conclusions: In this large series of prospectively collected acute stroke patients from Qatar, our study reveals that women are more likely to have a poor outcome when compared to men. Although there was a higher incidence of obesity and previous CAD in women, we were unable to explain the reasons for the poor outcome at 90 days and one year.

Hypothesis: Hypertriglyceridemia (HT) may increase the risk of stroke. Limited studies have shown that stroke severity and infarction size are smaller with HT. We explored the relationship between triglyceride and stroke risk factors, severity and outcome in a large prospective database. Methods: We interrogated the Qatar Stroke Database in all patients admitted between 2014-2022 with acute ischemic stroke and evaluated the relationship between vascular risk factors, stroke severity (measured on NIHSS), stroke type (TOAST classification) and the short- (mRS at 90 days) and long-term outcomes (MACE at 1 year) in patients with and without HT. Results: 6558 patients with ischemic stroke [mean age 54.6 ± 12. 9; male 82.1%) with normal (1.7 mmol/l - 4.4 ±4.6; p Conclusion: Onset of stroke occurs earlier in HT. The lower severity of symptoms and better prognosis evident with HT may in part be related to higher rates of lacunar stroke. Long-term MACE are however more frequently seen in HT subjects.

Objective: There are several challenges in implementing models for predicting stroke or stroke related outcomes. Most of these models have average concordance, and several of the important variables cannot be modified. In this study, we updated and performed a meta-analysis of commonly utilized models to predict stroke related outcomes. Our primary aim was to evaluate the discriminative ability of the concordance statistic by adding additional studies. Methods: Studies reporting c-index and SE (or 95% CI) for predicting stroke or related outcomes were included in our analysis. In addition to the c-index, total participants, year of publication, type of analytical method (survival, logistic regression, neural network, etc.) and type of outcome (predicting stroke or composite outcome) were utilized. Combined effect sizes with the random model, test for heterogeneity, and publication bias were considered. Egger’s test was used to assess funnel asymmetry. Results: Twenty-seven models were included (patients= 1762461; c-index=14, Harrell’s c-index= 13; only stroke =21, composite=6) in the analysis. Combined mean c-index was 0.76 (95% CI: 0.71, 0.81; 95% predictive interval: 0.59, 0.93). Combined mean Harrell’s c-index was 0.65 (95% CI: 0.61, 0.69; 95% predictive interval: 0.56, 0.74). Test of heterogeneity showed high variation between studies reporting c-index and Harrell’s c-index (I2=97.49% and 80.0% respectively). Egger’s test intercept was -2.1 (95% CI: -7.2, 3.0, P > .40) for c-statistic and 1.2 (95% CI: -1.2, 3.5, P > .32) for Harrell’s c-index studies. Conclusion: Current studies have not improved the prediction interval significantly as compared to our previous meta-analysis for predictive or explanatory model available for stroke risk. However, recent studies were found to be more inclusive of non-traditional biomarkers (e.g., genetic, or polygenic scores) and utilized various machine learning methods that were not used before.

Background: Acute ischemic stroke (AIS) patients show a good prognosis with Carotid endarterectomy (CEA). However, lowering short-term readmissions after CEA for AIS cases remains a significant challenge. Several machine learning (ML) models predicting readmissions fail to explain the predictors. Hence the utility of such ML models in clinical settings is limited. This study used interpretable machine learning (ML) methods to identify the predictors associated with 30-day readmission. Methods: We utilized the National Surgical Quality Improvement Program registry (2014-2017) for this study. Patients aged >18 years and who underwent CEA for AIS were included. ICD-9, ICD-10, and CPT codes were used to identify AIS and CEA cases. Decision Trees and Random Forest classification techniques were utilized to identify predictors of 30-day readmission. Results: A total of 22,373 AIS patients underwent CEA during the study period. The mean (SD) age of the patients was 70.7 (9.4) years, and the majority (61%) were males. About 80% were Non-Hispanic White, followed by non-Hispanic Black (4.6%). About 7% of AIS patients who underwent CEA had 30-day readmission. Random Forest classification and Decision Tree were able to provide clinically relevant predictors and cut-off values. For example, one of the top predictors was pre-operative Hematocrit, and its cut-off value of ≤33% with Diabetes showed a higher risk for readmission. Conclusion: Our study showed that interpretable ML models could be helpful for clinicians to stratify patients based on their pre-operative risk for a 30-day readmission and could help optimize management strategies for improving patient outcomes. Incorporating these cut-off values in EMR could help clinical decision-making and plan interventions to reduce readmissions by managing risk factors. This would improve the quality of care and save high healthcare costs.

Background and Purpose: Vascular risk factors are associated with transient ischemic attack (TIA), acute ischemic stroke (AIS) and corneal nerve damage. We have assessed if an improvement in vascular risk factors in patients with TIA and AIS is associated with corneal nerve regeneration. Methods: Patients with TIA or AIS and control subjects underwent assessment of clinical and vascular risk factors and corneal confocal microscopy (CCM) at baseline and 1-year follow up. Results: Eighty-one patients with TIA (n=28), AIS (n=53) and control subjects (n=56) were studied. Systolic blood pressure (SBP)( P =0.000), diastolic blood pressure (DBP) ( P =0.000) and HbA1 c (P=0.000) were significantly higher and HDL ( P =0.000), corneal nerve fiber length (CNFL) (P=0.000), corneal nerve fiber density (CNFD) (P=0.000) and corneal nerve branch density (CNBD) (P=0.003) were significantly lower in patients with TIA/AIS compared to controls. At follow up, there was a significant decrease in triglycerides (-0.37 mmol/l, P=0.005), total cholesterol (-1.12 mmol/l, P=0.000); LDL-cholesterol (-1.08 mmol/l, P=0.000), SBP (-24.76 mmHg, P=0.000), DBP (-14.24 mmHg, P=0.000) and HbA1 c (-0.50 mmol/l, P=0.027) and an increase in HDL (0.10 mmol/l, P=0.010), CNFL (1.48 mm/mm 2 , P=0.018), CNFD (1.66 no./mm 2 , P=0.024), and CNBD (26.90 no./mm 2 , P=0.000). The improvement in lipids and blood pressure was associated with an increase in corneal nerve parameters ( P Conclusions: An improvement in vascular risk factors in patients with TIA or AIS is associated with corneal nerve regeneration. CCM could be used to assess the effectiveness of risk factor reduction in patients with TIA or AIS.

Introduction: Treatment of acute ischemic stroke focuses on reperfusion but is limited by timing and other exclusions, and despite intervention, patients may sustain residual neurologic impairment. In addition to initial excitotoxic reactions following occlusion, upregulation of factors such as repulsive guidance molecule A (RGMa) inhibits cell survival and neuronal repair in infarcted regions. In vivo neutralization of RGMa is associated with decreased lesion size, reduced glial scarring, and enhanced functional recovery in animal models of cerebral artery occlusion; thus, RGMa suppression represents a novel therapeutic target due to its potential protective and restorative mechanisms. Elezanumab is an investigational monoclonal antibody that binds specifically to RGMa and is being evaluated for its function after ischemic stroke. Methods: Elezanumab in Acute Ischemic Stroke (EAISE) is a 52-week, phase 2a, randomized, double-blind, placebo-controlled study evaluating safety, efficacy, and pharmacokinetics of elezanumab in patients with acute ischemic stroke (NCT04309474). Patients will be randomized 1:1 within 23 hours since “last known normal” to receive elezanumab or placebo and every 4 weeks thereafter through week 48. Patients must be aged 30-90 years with a clinical diagnosis of acute ischemic stroke in anterior circulation and have a National Institutes of Health Stroke Scale (NIHSS) total score of 7 to 21. Patients who receive tissue plasminogen activator or endovascular therapy will be eligible if they continue to exhibit an NIHSS of 7 to 21 after treatment. Patients with evidence of seizure on stroke onset and history of repeated episodes of complex migraines will be excluded. Results: Projected enrollment is 120 patients across 45 sites in multiple countries. Primary endpoint is the NIHSS total score throughout the treatment period. Secondary endpoint is a favorable outcome based on the modified Rankin Scale, defined as a score of 0-2 at week 52. Exploratory outcomes include activities of daily living, cognition, mood, and fluid and imaging biomarkers. Conclusion: This phase 2 study will evaluate safety and efficacy of elezanumab, a novel therapeutic intervention to improve neurological recovery after acute ischemic stroke.

Introduction: The timing of direct oral anticoagulant (DOAC) after atrial fibrillation (AF)-related stroke is unknown. Most guidelines are inconsistent and based on expert opinion. We conducted a survey to evaluate the global practice patterns of this common clinical scenario. Methods: We used an electronic survey with practice-related demographic and clinical questions of 10 cases with different stroke severities and sizes: transient ischemic attack, small, medium, large, and strokes with hemorrhagic infarction and parenchymal hematoma. Results: A total of 242 clinicians from 21 countries completed at least one clinical scenario. The majority of the respondents were from Australia (36.4%) or Canada (22.7%). Stroke-specific sub-specialty training was self-reported in 82.2% of the respondents. Median (IQR) time spent dedicated to stroke patient care/research was 70 (60) % of total working hours. Only 14% of responding clinicians reported current participation in a randomized trial of DOAC initiation timing after AF-related stroke. Stroke size, severity, and the grade of hemorrhage if present seem to be determinants of the decisions. Lack of consensus was observed in moderate stroke, multi-territory infarcts, large stroke, and in the presence of HT. The majority of respondents would be willing to randomize patients with different stroke sizes and severities with/without HT in a clinical trial of early versus delayed initiation of DOAC after AF-related stroke. Conclusions: Decisions related to the timing of DOAC initiation after AF-related stroke vary globally. The variability in clinical practice will continue until randomized controlled trials are completed.

Background: Atrial fibrillation (AF) is a common cause of ischemic stroke; however, it is often difficult to detect. It is unclear whether specific infarct topography on magnetic resonance imaging (MRI) is associated with underlying AF. We aimed to objectively assess the infarct patterns on MRI in patients with acute ischemic stroke and determine imaging characteristics that are associated with AF. Methods: We conducted a subgroup analysis on patients randomized in Post-Embolic Rhythm Detection with Implantable vs External Monitoring trial (PER DIEM; NCT02428140) who had brain MRI. Two raters blinded to clinical details reviewed the MRI findings. Patients were divided to two groups (AF and non-AF) and descriptive statistics were used to characterize findings. Variables associated with new AF were analyzed using logistic regression and reported as odds ratios (OR) with 95% confidence interval (CI) and p -values. Results: Of the 300 patients who were randomized in the trial, 249 (83%) patients (59.4% male) with a mean age of 64.3 ± 13.1 years had MRI brain and were included in the analysis. Median (IQR) NIHSS was 0 (0 - 1), number of lesions was 2 (1 - 3), and diameter of lesion (mm) was 10.4 (5.8 - 21.1) mm. In this cohort of patients, imaging characteristics were not significantly associated with the detection of AF. Conclusions: Association between infarct topography and AF detection was not found in this study. Imaging characteristics cannot be relied upon to predict or exclude an underlying AF. Large prospective studies are suggested to examine the link between infarct topography and underlying AF.

Introduction: Early anticoagulation after acute ischemic stroke is usually avoided due to the risk of hemorrhagic transformation (HT). We aimed to assess the rate of radiological HT associated with direct oral anticoagulant (DOAC) initiation within 48 hours vs. > 48 hours in the post-stroke period. Methods: A pooled analysis of five studies of DOAC initiation within 14 days of ischemic stroke onset was conducted. The primary endpoint was incident radiographic HT on follow-up imaging. Secondary endpoints included symptomatic HT, new parenchymal hemorrhage (PH1 or asymptomatic PH2), recurrent systemic events, systemic hemorrhagic complications, mortality within the study period, final modified Rankin Scale score. The results were reported as odds ratio (OR) with 95% confidence interval (CI). Results: A total of 468 patients were enrolled. Median infarct volume was 1.35 (0-7.5) ml, and National Institutes of Health Stroke Scale was 1 (0-3). Incident radiographic HT was seen on follow-up scan in 29 patients. DOAC initiation within 48 hours from index event onset was not associated with incident HT (adjusted OR 0.67, [0.31 - 1.50] P =0.34). No patients developed symptomatic HT. Conversely, 25 patients developed recurrent ischemic events, 64% of which occurred within 14 days. Initiating DOAC within 48 hours of onset was not associated with a reduction in the risk of recurrent ischemic events (OR 0.47, [0.19 - 1.20] P =0.12). In contrast to HT, recurrent ischemic events were associated with poor functional outcomes (OR=6.8, [2.95 - 15.63], p Conclusions: Early DOAC initiation after stroke was not associated with increased incident HT risk. Recurrent ischemic events were common and associated with poor outcomes. These data may be useful for estimating outcome rates and sample size calculations in future trials of early versus late DOAC initiation after AF-related stroke.

Background and Purpose— Many patients with acute ischemic stroke are not eligible for thrombolysis or mechanical reperfusion therapies due to contraindications, inaccessible vascular occlusions, late presentation, or large infarct core. Sphenopalatine ganglion (SPG) stimulation to enhance collateral flow and stabilize the blood-brain barrier offers an alternative, potentially more widely deliverable, therapy. Methods— In a randomized, sham-controlled, double-masked trial at 41 centers in 7 countries, patients with anterior circulation ischemic stroke not treated with reperfusion therapies within 24 hours of onset were randomly allocated to active SPG stimulation or sham control. The primary efficacy outcome was improvement beyond expectations on the modified Rankin Scale of global disability at 90 days (sliding dichotomy), assessed in the modified intention-to-treat population. The initial planned sample size was 660 patients, but the trial was stopped early when technical improvements in device placement occurred, so that analysis of accumulated experience could be conducted to inform a successor trial. Results— Among 303 enrolled patients, 253 received at least one active SPG or sham stimulation, constituting the modified intention-to-treat population (153 SPG stimulation and 100 sham control). Age was median 73 years (interquartile range, 64–79), 52.6% were female, deficit severity on the National Institutes of Health Stroke Scale was median 11 (interquartile range, 9–15), and time from last known well median 18.6 hours (interquartile range, 14.5–22.5). For the primary outcome, improved 3-month disability beyond expectations, rates in the SPG versus sham treatment groups were 49.7% versus 40.0%; odds ratio, 1.48 (95% CI, 0.89–2.47); P =0.13. A significant treatment interaction with stroke location (cortical versus noncortical) was noted, P =0.04. In the 87 patients with confirmed cortical involvement, rates of improvement beyond expectations were 50.0% versus 27.0%; odds ratio, 2.70 (95% CI, 1.08–6.73); P =0.03. Similar response patterns were observed for all prespecified secondary efficacy outcomes. No differences in mortality or serious adverse event safety end points were observed. Conclusions— SPG stimulation within 24 hours of onset is safe in acute ischemic stroke. SPG stimulation was not shown to statistically significantly improve 3-month disability above expectations, though favorable outcomes were nominally higher with SPG stimulation. Beneficial effects may distinctively be conferred in patients with confirmed cortical involvement. The results of this study need to be confirmed in a larger pivotal study. Clinical Trial Registration— URL: https://www.clinicaltrials.gov . Unique identifier: NCT03767192.

Background: The extent of the pial collateral circulation may determine outcomes in an acute ischemic stroke. Experimental studies suggest that retinal vessel metrics and geometric patterning may predict the pial collateral status. We have undertaken a translational study to quantify and relate retinal vascular metrics to the grade of pial collaterals in patients with acute ischemic stroke. Method: 35 patients admitted with acute stroke underwent computed tomography angiography (OCT) and were graded as having good (n=20)(47.55 ± 10.65 years) or poor (n=15) (48.93 ± 10.91 years) pial collaterals and compared to healthy controls (n=21)(44.26 ± 10.15 years). Retinal images were generated using OCT and central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), artery-to-vein ratio (AVR), segmented fractal analysis and lacunarity, tortuosity index and fractal dimensions (capacity D 0 , information D 1 and correlation D 2 , curve asymmetry, singularity length and f-alfa-max using MONA software) were quantified. Results: Age ( p =0.709), BMI ( p =0.451), total cholesterol ( p =0.845), triglycerides ( p =0.679), LDL ( p =0.953), HDL ( p =0.361) and HbA 1c ( p =0.210) were comparable but the national institute of health stroke scale ( p =0.031) and modified Rankin Scale ( p =0.048) were higher in patients with poor compared to good collaterals. CRAE ( p =0.114), CRVE ( p =0.946), AVR ( p =0.114), lacunarity ( p =0.442), tortuosity index ( p =0.681), fractal analysis ( p =0.656), curve asymmetry ( p =0.619) and singularity length ( p =0.944) did not differ between patients with poor compared to good collaterals. However, fractal capacity D 0 (1.673 ± 0.029 vs 1.654 ± 0.025, p =0.042), fractal information D 1 (1.610 ± 0.027 vs 1.591 ± 0.024, p =0.036), fractal correlation D 2 (1.581± 0.028 vs 1.564 ± 0.024, p =0.060), and f alfa max (1.674 ± 0.027 vs 1.654 ± 0.025, p =0.030) were higher in patients with poor compared to good collaterals. Conclusion: This study shows differences in retinal vessel fractal dimensions between acute stroke patients with poor compared to good pial collaterals. This represents a non-invasive imaging method to define the pial collateral status and develop personalized intervention management strategies in acute ischemic stroke patients.

Background: The optimal timing of anticoagulation after stroke in patients with atrial fibrillation (AF) is unknown. Patients and methods: A prospective, open label study (NCT04435418) of patients with AF treated with apixaban within 14 days of ischemic stroke/TIA onset was conducted. Baseline and follow-up CT scans were assessed for hemorrhagic transformation (HT) and graded using European Cooperative Acute Stroke Study (ECASS) criteria. The primary endpoint was symptomatic HT. Incident HT rates were assessed as Objective Performance Criteria. Results: One-hundred AF stroke patients, with a mean age of 79±11 years were enrolled. Median infarct volume was 4 (0.5-10.75) ml. Median time from index event onset to apixaban initiation was 2 (1-6) days, and median baseline NIHSS was 4 (1-9). Asymptomatic HT on baseline imaging was present in 15 patients. Infarct volume (OR= 1.1, [1.02-1.12], P Discussion: Early apixaban treatment did not precipitate symptomatic HT after stroke. All HT was asymptomatic identified on imaging. Recurrent ischemic events were common and clinically symptomatic. Conclusions: Symptomatic HT rates are likely to be low in randomized trials of DOAC initiation post-stroke. Recurrent ischemic stroke may be the major clinical outcome.

Background and Purpose: An ipsilateral non-obstructive carotid atherosclerosis (NOCA), defined as carotid plaque with Methods: A search of Pubmed and Ovid-Embase identified observational studies reporting carotid plaque imaging features in patients with cryptogenic stroke, from inception to July 15, 2019. The prevalence of NOCA with high-risk features in ipsilateral and contralateral carotid was determined by pooling study-specific estimates using a random-effect meta-analysis. Results: Six prospective studies enrolling a total of 255 participants with unilateral ischemic stroke in the anterior circulation were included. Carotid arteries were imaged with ultrasound, computed tomography or MRI to identify echolucency, ulceration, intraplaque hemorrhage, thrombus, or thickness ≥ 3 mm. The pooled prevalence of NOCA with high-risk features in the ipsilateral carotid was 34.0% (95% CI: 25.7 – 42.9) compared to 7.3 % (95% CI: 0.8 – 18.1) in the contralateral carotid. The odds ratio of finding a plaque with high-risk features in the ipsilateral versus the contralateral carotid was 4.1 (95% CI: 2.0 – 8.7). Conclusion: Plaques with high-risk features are four times more prevalent in the ipsilateral compared to the contralateral carotid artery in patients with cryptogenic stroke, suggesting a relationship to stroke risk. These features may aid in etiologic classification of stroke and risk stratification for secondary prevention therapy.

Background: Sphenopalatine ganglion (SPG) stimulation enhances collateral flow, stabilizes blood-brain barrier, and showed evidence of benefit in patients with confirmed cortical involvement (CCI) when started 8-24h after onset in the ImpACT-24B randomized trial. To characterize SPG stimulation benefit magnitude, we derived number needed to treat (NNT) values based on shifts over all levels of 3 month global disability. Methods: From the distribution of the 7-level modified Rankin Scale (mRS) at 3m in SPG- and sham-stimulation CCI patients, NNT to benefit (NNTB) and NNT to harm (NNTH) values were derived by automated (algorithmic min-max) and expert generation of joint outcome distribution tables. For dichotomized mRS outcomes, net NNT values were derived directly from absolute risk differences. Results: Among 520 patients with confirmed cortical infarction ineligible for thrombolysis, 244 were treated with SPG and 276 with sham stimulation. NNT values for dichotomized and shift mRS outcomes are shown in the Table. Of the 6 possible binary cutpoints on the mRS, 4 showed more favorable outcome with SPG stimulation. The dichotomized endpoint with the greatest group difference was ambulatory and capable of bodily self-care (mRS 0-3), 62.3% vs 51.1%, NNTB 8.9. Across all 6 individual possible dichotomizations of the mRS, the NNTB ranged from 8.9 to -166.7. For shifts by 1 or more levels across all 6 transitions of the mRS, the biologically most plausible NNTB was 5.7 (IQR 5.6-6.5), NNTH 34.5 (IQR 30.3-40.0), and net NNTB 6.8 (IQR 6.5-7.7), These values correlated closely with the automatically derived net NNTB of 5.9. Conclusions: The findings of this pivotal trial indicate that, out of every 1000 CCI patients treated with SPG stimulation, 146 patients will have a less disabled 3-month outcome, including 76 more who will be functionally independent. SPG stimulation can substantially improve the outcome of thrombolysis-ineligible acute ischemic stroke patients.

Background: There are gender differences in the short-term prognosis following acute stroke suggesting that outcome is less favorable in women. Factors contributing to this poor outcome include preexisting morbidity, stroke severity and higher age. Most previous studies have looked at short-term prognosis. PURPOSE: We investigated whether gender differences have a differential impact on incidence of short-term outcome and long-term major adverse cardiovascular events (MACE) including stroke, myocardial infarction, unstable angina, coronary revascularization procedure, and death in patients with suspected acute stroke. Methods: The study used a prospective cohort of Qatari patients with suspected acute stroke between January 2014 and February 2019. We calculated the modified Rankin score (mRS) at discharge and 90-days (short-term) and MACE (long-term) outcomes in both genders. To determine the independent predictor for MACE, the Cox proportional hazards regression analysis was used and summarized as hazard ratio and 95% confidential interval. Results: A total of 1372 patients identified. At 90-days, women found to have significantly poorer outcome (34.0% vs 23.4%, p Conclusion: Our results show that despite higher mortality and poor outcome at 90-days, the long-term outcome in women did not show any significant difference from men in this cohort. This may be related to older age and presence of cardiovascular risk factors.